AntriaBio

Focused on Breakthrough Therapies for Unmet Needs in Metabolic Diseases and Orphan Indications

Lead product candidate AB101 is a recombinant human basal insulin formulated for once-weekly injection with the potential to significantly advance the treatment paradigm for insulin replacement therapy.

Learn More

Investor Relations